Abstract
Dysregulation of Th17 cell differentiation and pathogenicity contributes to multiple autoimmune and inflammatory diseases. Previously growth hormone releasing hormone receptor (GHRH-R) deficient mice have been reported to be less susceptible to the induction of experimental autoimmune encephalomyelitis. Here, we show GHRH-R is an important regulator of Th17 cell differentiation in Th17 cell-mediated ocular and neural inflammation. We find that GHRH-R is not expressed in naïve CD4+ T cells, while its expression is induced throughout Th17 cell differentiation in vitro. Mechanistically, GHRH-R activates the JAK-STAT3 pathway, increases the phosphorylation of STAT3, enhances both non-pathogenic and pathogenic Th17 cell differentiation and promotes the gene expression signatures of pathogenic Th17 cells. Enhancing this signaling by GHRH agonist promotes, while inhibiting this signaling by GHRH antagonist or GHRH-R deficiency reduces, Th17 cell differentiation in vitro and Th17 cell-mediated ocular and neural inflammation in vivo. Thus, GHRH-R signaling functions as a critical factor that regulates Th17 cell differentiation and Th17 cell-mediated autoimmune ocular and neural inflammation.
Similar content being viewed by others
Introduction
T helper 17 (Th17) cells are a subset of CD4+ T cells characterized by the secretion of interleukin-17 (IL-17) and expression of a nuclear transcription factor, retinoic acid receptor-related orphan receptor gamma t (RORγt)1,2. Th17 cells regulate the host defense against extracellular pathogens and in the pathogenesis of many autoimmune diseases, including autoimmune uveitis and multiple sclerosis3. Signaling from T cell receptor and cytokines IL-6 and transforming growth factor-β (TGF-β) induce the differentiation of naïve T cells into Th17 cells via mediating phosphorylation of STAT3, which is further amplified by signaling from IL-23 and IL-21 in a positive feedback loop4,5,6,7. The phosphorylation of STAT3 can induce the expression of transcription factors RORγt and RORα that acts as a master switch to regulate the characteristic set of cytokines IL-17A, IL-17F, IL-21, and IL-22 in Th17 cells3,8. However, it has been reported that Th17 cells induced by IL-6 and TGF-β are not sufficient to elicit autoimmune diseases, which require a co-stimulation of IL-23, or another co-stimulation of IL-6, IL-1β, and IL-23 in the absence of TGF-β9,10. In addition to these cytokines, however, other factors regulating the differentiation and pathogenicity of Th17 cells remain not very well understood.
Autoimmune uveitis is a sight-threatening disease characterized by a heterogeneous group of intraocular inflammatory disorders. It often occurs with systemic autoimmune syndromes such as ankylosing spondylitis, Behçet’s disease and Vogt–Koyanagi–Harada (VKH) disease, in which Th17 cells were considered to be associated with the disease initiation and development11,12,13. In the experimental autoimmune uveitis (EAU), an animal model mimicking human autoimmune uveitis14, Th17 cells were found to be a predominantly pathogenic mediator in the development of uveitis by producing a set of proinflammatory cytokines, including IL-17A, IL-17F, IL-22, and GM-CSF15,16. Unexpectedly, treating uveitis by neutralizing IL-17A, the major pathogenic cytokine, failed to diminish the disease due to the increase of other Th17-lineage cytokines through a negative feedback loop17. These studies highlight the involvement of other potential factors or mechanisms to regulate Th17 cells and their associated proinflammatory cytokines in autoimmune inflammation.
Growth hormone-releasing hormone (GHRH) is a neurosecretory peptide hormone synthesized by the hypothalamus. Its binding to specific GHRH receptors (GHRH-R) in the pituitary regulates the synthesis of growth hormone (GH). In multiple organs, GH induces the production of insulin-like growth factor 1 (IGF-1), which was recently reported to be a key regulator for Th17-regulatory T (Treg) cell balance in autoimmunity18,19,20. We have demonstrated that GHRH and GHRH-R were expressed in multiple ocular tissues, including the iris, ciliary body, retina, and eye-infiltrating leukocytes in the endotoxin-induced uveitis (EIU) animal model21. GHRH signaling was involved in ocular inflammation after lipopolysaccharide (LPS) insults, as the expression of GHRH-R was elevated along with the proinflammatory cytokines of IL-1β and IL-6 in the iris and ciliary body, which can be reduced by the GHRH antagonist, a competitive inhibitor of the receptors21. In previous studies, GHRH-R was found in T lymphocytes, which regulate immune response to aging22. In addition, GHRH was reported to stimulate the secretion of IL-17A from human peripheral blood mononuclear cells23. In another study, GHRH-R deficient mice were reported to be less susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), a Th17 cell-mediated disease model mimicking human multiple sclerosis24,25. GH was found to be able to increase T cell proliferation and spleen size in these EAE mice25. Interestingly, without exogenous peptide immunization, GHRH-deficient mice did not affect thymic T cell development26. In agreement with these results, in cattle, myogenic expression of GHRH led to more abundant T cell lineages of CD2+, CD4+CD25+, and CD4+CD45R+27. In humans, administration of the GHRH analog resulted in a significant increase of cells expressing various T cell receptors, while no difference was observed in T cells expressing CD3, CD4, or CD828. In addition, GHRH-R was found in human sarcoidosis granuloma, a Th17 cell-mediated inflammatory disorder resulting in multisystemic granuloma, which can be alleviated by GHRH antagonist with a reduced level of IL-17A in an in vitro granuloma model29.
In this work, we hypothesize that GHRH-R signaling is involved in the pathogenesis of Th17-mediated autoimmune inflammation through the interaction with Th17 cells and their associated cytokines. Our results demonstrate that GHRH-R is preferentially expressed in Th17 cells, but not Th1, Th2, or Treg cells. GHRH-R signaling activates the JAK-STAT3 pathway, increases the phosphorylation of STAT3, enhances both non-pathogenic and pathogenic Th17 cell differentiation and favors the gene expression signatures of pathogenic Th17 cells. The inhibition or deficiency of GHRH-R reduces Th17 cell differentiation and alleviates Th17 cell-mediated autoimmune ocular and neural inflammation.
Results
Elevated expression of GHRH and GHRH-R in the retina of EAU mice
To investigate the impacts of GHRH and GHRH-R in autoimmune diseases, EAU, a well-established autoimmune disease animal model, was used. We first investigated the expression of GHRH and GHRH-R in the retina of EAU mice. This was done by immunizing mice with interphotoreceptor retinoid-binding protein (IRBP)1-20 peptide (Fig. 1a). Compared with mice with mock induction, EAU-induced mice had elevated gene expression of Ghrh and Ghrhr in the retina (Fig. 1b). Moreover, the gene expression of Ghrhr splice variant 1 (Sv1), reported to express in normal human tissues and tumors30,31, was also elevated in the retina of EAU mice (Fig. 1b). Consistently, immunofluorescence staining showed that GHRH and GHRH-R were markedly increased in ganglion cell layer and the inner nuclear layer of the retina (Fig. 1c). Collectively, the increased mRNA and protein of GHRH and GHRH-R in the retina of EAU mice suggested the GHRH-R signaling regulates responses to EAU induction. Alternatively, the enhanced expression of GHRH and GHRH-R in the retina could be a response to the inflammation.
GHRH-R deficiency ameliorates autoimmune ocular inflammation
To investigate the impacts of GHRH and GHRH-R in uveitis, Ghrhrlit/lit mice, with an amino acid substitution mutation D60G in the GHRH receptor resulting in the reduction of the GHRH-GH-IGF-1 signaling, were challenged with EAU32,33. As autoimmune uveitis is a chronic inflammatory disease in the eyes, we employed live ocular imaging technologies, confocal scanning laser ophthalmoscope (cSLO), and optical coherence tomography (OCT) to follow the morphological retinal changes in live mice34. cSLO and OCT examinations showed that GHRH-R deficient mice developed attenuated uveitis in terms of optic nerve head inflammation, vitreous and retinal infiltrates, retinal edema, and vasculitis (Fig. 1d–f and Supplementary Fig. 1a, b). Moreover, quantified evaluation of retinal-choroidal thickness (RCT) by OCT and visions of photopic and scotopic B-wave amplitudes by electroretinography (ERG) confirmed that Ghrhrlit/lit mice exhibited reduced fold change of RCT and better visions in dark and light adaption during the development of EAU, compared with wild-type (WT) mice (Supplementary Fig. 1a–d). Consistently, lower levels of histopathologic features in terms of chorioretinal infiltrates and extensive retinal structural damage corroborated with the alleviated uveitis in mice with deficient GHRH-R (Fig. 1g). We also immunized WT and Ghrhrlit/lit mice with IRBP651-670 peptide, which has been reported to induce more severe EAU35. Compared with WT mice, Ghrhrlit/lit mice immunized with IRBP651-670 developed less EAU in terms of disease score and quantified fold change of retinal-choroidal thickness (Supplementary Fig. 1e–h). In these Ghrhrlit/lit mice, multiple cell types were deficient in GHRH-R. It is important to investigate whether lacking GHRH-R in the retina or in the effector cells contributed to the alleviated uveitis in Ghrhrlit/lit mice.
GHRH-R deficiency impairs the pathogenicity of Th17 cells in autoimmune ocular inflammation
As EAU has been reported as a Th1 and Th17-mediated autoimmune disease11, to evaluate the impact of GHRH-R deficiency during EAU, T cell subset in the spleen, eye-draining lymph nodes, and eyes were analyzed. Given the importance of the GHRH-R in the lymphopoiesis and thymic development36,37, the effects of GHRH-R on the T cell development at the steady state (without EAU induction) was first investigated (Supplementary Fig. 2a–e). No alterations in the percentage of various T cell populations (CD4+, CD8+, CD4+CD8+, CD25+, AnnexinV+, CD44+CD62L-, IFN-γ+, IL-4+, IL-17A+, and Foxp3+) were found, indicating that GHRH-R exerted a minimal impact to the development and maintenance of T cells at the steady state, in agreement with previous studies26. After immunization, the activation of T cell was not affected (Supplementary Fig. 3a–d). However, there was a marked reduction in the percentage of CD4+ T cells expressing IL-17A, but not Th1, Th2, and Treg cell subsets, in spleen and eye-draining lymph nodes (Fig. 2a, b). The pathogenic IL-17A+IFN-γ+ double positive CD4+ T cells were also significantly lower in eye-draining lymph nodes and spleen (Fig. 2b and Supplementary Fig. 3i). No alterations in various T cell populations under the EAU-induced condition (CD4+, CD8+, CD25+, CD44+, and CD69+) were found (Supplementary Fig. 3a–d). To further investigate the pathogenicity of GHRH-R deficient Th17 cells in EAU, CD4+ T cells isolated from the uveitic eye were analyzed. GHRH-R deficient mice showed a significantly lower frequency of IL-17A+CD4+ T cells co-expressing the pathogenic Th17 cytokines GM-CSF or IFN-γ in their eyes (Fig. 2c). Accordingly, mRNA levels in genes associated with pathogenic Th17 cells, including Il17a, Il17f, Il22, and Csf2 were decreased, while Il10 was increased, in the CD4+ T cells isolated from the eyes of Ghrhrlit/lit mice. There is no difference in the expression of gene C-C motif chemokine receptor 6 (Ccr6), a chemokine receptor critical for Th17 cell migration into the inflamed tissues38 (Fig. 2d), indicating GHRH-R deficiency did not alter the migration of these eye-infiltrating CD4+ T cells.
To further confirm the impact of GHRH-R on the pathogenicity of IRBP-specific Th17 cells in uveitis, the capability of pathogenic Ghrhrlit/lit Th17 cells to induce uveitis was assessed by adoptive transfer into recipient mice without IRBP injection. Donor WT and Ghrhrlit/lit mice were immunized with IRBP1-20 and after 10 days, CD4+ T cells were purified from the spleen and draining lymph nodes and cultured under Th17 polarizing condition with IRBP1-20 for 3 days. Then the equal amount of live CD4+ T cells were transferred into naïve WT or Ghrhrlit/lit recipient mice (Fig. 2e). Both WT and Ghrhrlit/lit recipient mice receiving the IRBP-specific T cells from WT donor mice were able to develop a similar onset and severity of uveitis (Fig. 2f and Supplementary Fig. 3e–h). However, the IRBP-specific T cells isolated from Ghrhrlit/lit donor mice could not elicit uveitis in WT or Ghrhrlit/lit recipient mice (Fig. 2f and Supplementary Fig. 3e–h). These data indicate GHRH-R deficiency impaired the pathogenicity of Th17 cells in autoimmune uveitis, despite wild-type GHRH-R was still expressed in the retina.
Th17 cells express GHRH-R throughout Th17 differentiation
To investigate the impacts of GHRH-R in T cells, mRNA expression of Ghrhr and Sv1 was initially measured in T cell subsets. Naïve T cells were isolated and gated as CD4+CD25-CD62L+CD44- T cells (Supplementary Fig. 4a), followed by in vitro differentiation into Th0, Th1, Th2, Th17, and induced regulatory T (iTreg) cells. Gene expression of Ghrhr and Sv1 was constitutively expressed at low level in naïve T cells and was upregulated in all T cell subsets at 48 h under selective polarizing conditions (Fig. 3a and Supplementary Fig. 4d). Notably, Th17 cells showed a significant increase in mRNA expression of Ghrhr and Sv1 compared with Th0 cells (Fig. 3a and Supplementary Fig. 4d). Furthermore, during Th17 cell differentiation along various time points, Ghrhr gene expression was increasingly upregulated from 12 h, peaking at 48 h, and then declined at 96 h in comparison to Th0 cells, which showed a constantly lower level of Ghrhr along 96 h (Fig. 3b). Ghrhr gene expression in cells under Th1, Th2, or iTreg conditions showed a slight increase from 12 h and peaked at 48 h, followed by a gradual decrease to the original levels at 96 h (Supplementary Fig. 4e). Immunofluorescence staining confirmed that GHRH-R was hardly detected in naïve T cells, whereas it was expressed and localized predominantly on the cell membrane of Th17 cells (Fig. 3c). In addition, flow cytometry analysis showed the GHRH-R expression in the IL-17A+CD4+ T cells was higher than that in the IL-17A-CD4+ T cells from the same samples (Fig. 3d). Taken together, these data indicated GHRH-R, similar to IL-23R, is rarely expressed in naïve T cells, while it is expressed in Th17 cells during differentiation39. However, unlike IL-23R being specifically expressed in Th17 cells, GHRH-R is also expressed in other T cell subsets, indicating that the expression of GHRH-R during differentiation of all T cells is not only induced by the signaling factors (IL-6 and TGF-β) required for the differentiation into Th17 cells.
GHRH-R is critical to Th17 differentiation
To investigate whether GHRH-R is critical to T cell differentiation, naïve CD4+ T cells from WT and Ghrhrlit/lit mice were activated with anti-CD3 and anti-CD28 antibodies and cultured under Th1, Th2, Th17, or iTreg cell-polarizing conditions. GHRH-R-deficient naïve T cells had a reduced capacity for differentiation into Th17 cells, as evidenced by lower expression of IL-17A and RORγt (Fig. 4a–d). Meanwhile, GHRH-R deficiency did not affect T cell differentiation into Th1, Th2, or iTreg cells, which was assessed by the expression of the cytokines IFN-γ and IL-4, and transcription factors T-bet, GATA3, and Foxp3 (Fig. 4a–d).
Th17 cells generated in vitro in stimulation with TGF-β and IL-6 were reported to be non-pathogenic due to their incapability to provoke autoimmune disease after transferring into mice10. However, additional in vitro exposure to IL-23 is able to render these cells pathogenic, as does their differentiation in the absence of TGF-β, with a combination of IL-6, IL-1β, and IL-239,10. Given GHRH-R deficiency impaired the differentiation of non-pathogenic Th17 cells, we further examined its impact on the differentiation of Th17 under two different pathogenic conditions: (1) IL-6, TGF-β, and IL-23; (2) IL-6, IL-1β, and IL-23. Our results showed that Ghrhrlit/lit T cells had reduced IL-17A production after differentiating in both pathogenic Th17 conditions, compared with WT. (Fig. 4e, f). To further address the mechanism whereby GHRH-R deficiency impaired Th17 cell differentiation without any additional treatment of GHRH ligands in the cell culture medium, we investigated whether GHRH, the natural ligand for GHRH-R, was produced by Th17 cells to enhance their own differentiation. Unexpectedly, the expression of Ghrh was not detectable from Th17 cells under the stimulation of IL-6 with TGF-β or IL-6, IL-1β with IL-23. Additionally, other cytokine receptors associated with Th17 cell differentiation were also measured. Gp130, Il1r, and Il21r expression showed no significant changes in Ghrhrlit/lit Th17 cells, while Il23r expression was decreased in Ghrhrlit/lit T cells under stimulation with IL-6 and TGF-β or IL-6, IL-1β, and IL-23 (Fig. 4g, h). Moreover, GH and IGF-1 have been reported to regulate T cell development40,41. To investigate the influence on T cell differentiation by GHRH-R downstream molecules GH and IGF-1 produced by the T cell itself, antibodies against GHRH, GH, and IGF-1 were applied to neutralize these molecules. Significantly decreased expression of IL-17A were observed in WT Th17 cells, but not in Ghrhrlit/lit Th17 cells, in the presence of anti-GHRH antibody during differentiation, indicating that GHRH in the cell culture environment could influence the differentiation of Th17 cells (Fig. 5a). However, neutralization by antibodies against GH and IGF-1 did not alter IL-17A production between WT and Ghrhrlit/lit Th17 cells (Fig. 5a).
We next examined the influences of GHRH-R signaling in the naïve CD4+ T cell differentiation into Th17 cells with or without exogenous GHRH-R ligands by using human GHRH (hGHRH), GHRH agonist MR-409 and antagonist MIA-602. Both MR-409 and MIA-602 exhibit much higher affinity in receptor binding and a longer half-life in serum compared with hGHRH42,43. Naïve CD4+ T cells isolated from WT and Ghrhrlit/lit mice were cultured with hGHRH, MR-409, and MIA-602 under Th17 cell-polarizing conditions. hGHRH significantly enhanced the differentiation into Th17 cells in WT cells upon the stimulation with IL-6 and TGF-β, as did GHRH agonist, which showed a more potent effect. Nevertheless, Ghrhrlit/lit Th17 cells showed no response to hGHRH or GHRH agonist over differentiation. GHRH antagonist reduced Th17 cell differentiation in WT cells to a comparable level in Ghrhrlit/lit cells (Fig. 5b). Moreover, these GHRH analogs exhibited dose-dependent effects (Supplementary Fig. 5a–c). Consistently, the Th17-specific effect was observed in both GHRH agonist and antagonist as both of which failed to influence the Th1, Th2, and iTreg cell differentiation (Supplementary Fig. 5d, e). Collectively, these data indicate that the signaling from GHRH and its agonist binding to GHRH-R promotes the differentiation into Th17 cells, which can be abolished by blocking its signaling using an anti-GHRH antibody or GHRH antagonist. Only low expression levels of IFN-γ could be detected under these Th17 cell-polarizing conditions. Therefore pathogenic Th17 cells could not be quantified by co-staining cells with IL-17A and IFN-γ (Supplementary Fig. 5l–m), which was different from the in vivo data. Furthermore, we were unable to detect the expression of IL-9, a regulator of pathogenicity in Th17 cells44, whereas IL-10 expression is significantly higher in GHRH-R deficient cells than in WT cells (Supplementary Fig. 5n). To further investigate the effects of GHRH-R signaling in Th17 cells, naïve T cell from WT and Ghrhrlit/lit mice were polarized into Th17 cells for 3 days in vitro. The resulting cells were starved in a serum-free medium for 4 h and then exposed to GHRH agonist for 30–60 min, followed by RT-qPCR analysis. The expression of genes associated with pathogenic Th17 cells, including Il17a, Il17f, Il22, Il23r, Rorc, Rora, and Hif1a were reduced in Ghrhrlit/lit Th17 cells, whereas Batf and Irf4 were not altered (Fig. 5c). We further verified our results in the Ghrhr knocked down cells. siRNA knocked down of Ghrhr in WT naïve T cells led to less differentiation towards Th17 cells (Supplementary Fig. 5k). These data suggest that GHRH-R signaling promoted, while inhibition of GHRH-R signaling reduced, the differentiation and pathogenicity of Th17 cells.
To assess whether GHRH-R deficiency affects T cell division, proliferation, viability, and activation in vitro, we activated naïve CD4+ T cells from WT and Ghrhrlit/lit mice with anti-CD3 and anti-CD28 under Th17 polarizing conditions with or without the addition of GHRH agonist for 3–5 days. First, we analyzed the dilution of CellTrace violet dye after Th17 cell culture for 3 days. The vast majority of WT and Ghrhrlit/lit Th17 cells with or without additional GHRH agonist entered the cell division (Fig. 5d). Additionally, WT and Ghrhrlit/lit Th17 cells, with or without additional GHRH agonist, no significant difference in cell viability (Supplementary Fig. 5f, g) and activation mediated by T cell receptor (TCR) were observed, as indicated by a similar expression of markers of TCR activation (CD44, CD25, and CD69) (Supplementary Fig. 5h–j). Our results suggested GHRH-R deficiency does not affect T cell division, proliferation, viability, and activation.
GHRH signaling promotes STAT3 phosphorylation in Th17 cell differentiation
The aberrant Janus kinase (JAK)-STAT3 signaling has been reported in various immune disorders5,45. Our previous study demonstrated that GHRH-R signaling through the JAK2-STAT3 pathway directly mediated the inflammatory responses to LPS insults in the human ciliary body and mouse iris21. To investigate whether GHRH-R signaling mediates Th17 cell differentiation via the JAK-STAT3 pathway, naïve T cells from WT and Ghrhrlit/lit mice were cultured in Th17 polarizing conditions for 3 days. Then these cells were starved in the serum-free medium with or without ruxolitinib (Rux), a JAK 1/2 inhibitor, for 4 h prior to a pulse with GHRH agonist or antagonist for 30 min. The phosphorylation of STAT3 (p-STAT3) Y705 was determined by flow cytometry. The results showed no significant difference of p-STAT3 Y705 between WT and Ghrhrlit/lit Th17 cells without stimulation by GHRH ligands (Fig. 5e). After a pulse with GHRH agonist, WT Th17 cells had increased p-STAT3 Y705, which was decreased by blocking JAK1/2 with Rux, compared with Ghrhrlit/lit Th17 cells. As expected, the GHRH antagonist failed to elevate p-STAT3 Y705 in both WT and Ghrhrlit/lit Th17 cells (Fig. 5e). We next sought to investigate the time-dependent effects of GHRH signaling in the p-STAT3 Y705 in Th17 cells from 0–60 min. The p-STAT3 Y705 in WT Th17 cells had been steadily increasing from 15 min after the pulse with GHRH agonist, peaked at 30 min, and followed by a slight decrease at 60 min. Conversely, Ghrhrlit/lit Th17 cells had no response to the pulse with GHRH agonist (Fig. 5f). Finally, we determined the importance of the GHRH-R-JAK-STAT3 pathway mediating Th17 cell differentiation. Blocking of JAK1/2 by Rux or inhibiting the activation of STAT3 by a Stattic completely abolish GHRH agonist-induced signaling, resulting in significantly reduced production of IL-17A in WT CD4+ T cell during differentiation (Fig. 5g). These data demonstrated that GHRH-R signaling influences Th17 cell differentiation via GHRH-R-JAK-STAT3 pathway.
GHRH agonist promotes, while GHRH antagonist ameliorates, Th17-mediated ocular inflammation
Our results showed that GHRH-R is required for Th17 cell differentiation and Th17 cell-mediated autoimmune ocular inflammation via the use of genetically modified mice with mutated GHRH-R. To further confirm these findings from a pharmacological perspective, GHRH agonist MR-409 and antagonist MIA-602 were injected daily from day 10 to day 21 after immunization into WT mice with EAU induction. Clinical examinations by cSLO and OCT, and ocular histology showed that compared with the vehicle group (EAU + DMSO), mice treated with GHRH agonist (EAU + MR-409) developed more severe uveitis, while mice treated with GHRH antagonist (EAU + MIA-602) produced less uveitis (Fig. 6a, b and Supplementary Fig. 6a–c). Consistently, qRT-PCR analysis of RNA from isolated retina revealed that compared with the vehicle group (EAU + DMSO), the expression of cytokines for pathogenic Th17 cells, including Il17a, Il17f, and Cfs2 were upregulated by GHRH agonist, while downregulated by GHRH antagonist (Fig. 6d). Although the expression of Ghrh was elevated significantly in the retina of mice immunized with IRBP compared with mice mock treated with PBS, neither GHRH agonist nor antagonist altered the expression of Ghrh in these retinae (Fig. 6d). To further confirm whether GHRH agonist or antagonist mediated the autoimmune ocular inflammation by regulating pathogenic Th17 cells in vivo, we examined the population of T cell subsets, as well as T cell activation and apoptosis in the spleen, draining lymph nodes, and eyes. Consistently, no alteration was observed in the population of CD4+ and CD8+ T cells and the markers of T cell activation, including CD25, CD69, CD44, and CD62L (Supplementary Fig. 6d–g). Consistent with our in vitro experimental results, IRPB1-20 immunized mice treated with GHRH agonist have significantly increased IL-17A+CD4+ T cells but not other T cell subsets in the spleen, eye-draining lymph nodes, and eyes. Conversely, GHRH antagonist-treated mice have decreased IL-17A+CD4+ T cells, as well as the pathogenic Th17 cells (Fig. 6e–g and Supplementary Fig. 6h). In addition, in the eye, the pathogenic Th17 cells expressing IL-17A+GM-CSF+ or IL-17A+IFN-γ+ were also increased in the GHRH agonist treated mice but were reduced in the GHRH antagonist-treated mice (Fig. 6g). We next enriched the CD4+ T cells from the eyes and analyzed the expression of genes associated with pathogenic Th17 cells. The expression of pathogenic cytokines of Th17 cells, including Il17a, Il17f, Il22, and Csf2, were upregulated in mice treated with GHRH agonist and were downregulated by GHRH antagonist (Fig. 6h). The expression of Ccr6 was not altered by GHRH agonist and antagonist (Fig. 6h). Consistent with data from GHRH-R deficient mice challenged with uveitis, GHRH antagonist protected mice from uveitis as well, while GHRH agonist promoted it. Collectively, our data confirmed that GHRH signaling is required for the differentiation of Th17 cells in autoimmune ocular inflammation.
GHRH-R deficiency ameliorates autoimmune neuroinflammation
Given the importance of GHRH signaling in Th17 differentiation and Th17 cell-mediated autoimmune ocular inflammation, we next addressed if this pathway also mediates other Th17 cell-driven autoimmune diseases. WT and Ghrhrlit/lit mice were immunized with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide to induce EAE, a mouse model mimicking human multiple sclerosis46. Mice with deficient GHRH-R produced reduced inflammation in the central nervous system (CNS) in terms of body weight loss, peak disease score, and histopathology (Supplementary Fig. 7a–d). Importantly, there was a significant reduction in CD4+ IL17A+ T cells in the draining lymph nodes, spinal cord, and brain in Ghrhrlit/lit EAE mice (Supplementary Fig. 7e–g). In addition, the CNS-pathogenic Th17 cells (IL-17+IFN-γ+ or IL-17A+GM-CSF+) were decreased significantly in the CNS (Supplementary Fig. 7f, g). Altogether, these data indicated that GHRH-R deficiency protects mice from Th17-mediated autoimmune neuroinflammation.
Discussion
The neuroendocrine system and the immune system are known to communicate with each other. Ligands and their receptors have been reported to be shared by cells of both systems47. Recently, the receptor of GHRH, a neuropeptide secreted from the hypothalamus, has been found on T cells, and upon binding to its ligands, the synthesis and secretion of GH from T cells are induced, which can serve as a paracrine/autocrine regulation to indirectly facilitate immune responses48. However, the impacts of GHRH-R in T cells remain not very well understood. In this study, Ghrhrlit/lit mice were employed to study the influence of GHRH-R signaling in Th17 cell differentiation genetically. In addition, to eliminate the underlying alterations in immune homeostasis, growth, and development caused by GHRH-R deficiency, GHRH agonist and antagonist were treated in WT mice to further verify the effects of enhancing or inhibiting the GHRH-R signaling. Furthermore, to investigate whether GHRH-R signaling acts as a critical regulator in Th17 cell-mediated inflammation, two mouse models of autoimmune diseases, the EAU and EAE models, were employed. Our results showed that GHRH-R signaling is essential for Th17 cell differentiation and Th17 cell-mediated autoimmune ocular and neural inflammation because the deficiency or inhibition of GHRH-R signaling resulted in (1) reducing non-pathogenic and pathogenic Th17 cell differentiation in vitro; (2) via suppressing the phosphorylation of STAT3 through JAK-STAT3 pathway; (3) impairing the pathogenicity of Th17 cells; and (4) suppressing autoimmune ocular and neural inflammation.
GHRH-R is barely detectable in naïve T cells, whereas co-stimulatory signals from TCR and CD28 of T cells remarkably induce the expression of the mRNA and protein of GHRH-R as well as the splicing variant GHRH-R SV1. We found that GHRH-R SV1 expression was increased in the activated T cell subset; however, its impact remains unclear. Although the production of GHRH-R on activated T cell does not exhibit a Th cell type-specific pattern, we found that the differentiated Th17 cells have higher GHRH-R expression than other T cell subsets, indicating the synergistic effects of IL-6 or TGF-β in stimulating the expression of GHRH-R. This is similar to IL-23R that is not expressed on naïve T cells, but increasingly expressed on activated T cells upon differentiation into Th17 cells1,39. Moreover, there is a strong correlation between GHRH-R and IL-17A production. Th17 cells with higher level of GHRH-R produce more IL-17A. Thus, our results suggest GHRH signaling is not involved in the initial differentiation of Th17 cells but appears to promote the production of IL-17A in activated T cells in the late phase of Th17 differentiation. On the other hand, the differentiation of other T cell subsets, including Th1, Th2, and iTreg, are not affected by the GHRH-R signaling.
Previous studies showed that IL-23R can be induced by IL-6/IL-21 together with low amounts of TGF-β in a RORγt-dependent manner. By responding to IL-23, IL-23R further promotes the synthesis of RORγt in return via enhancing the STAT3 signaling, which is essential for the expansion and stabilization of Th17 cells4,5,7. In our study, GHRH-R deficient T cells stimulated by IL-6 plus TGF-β, or a combination of IL-6, IL-1β, and IL-23, showed a reduced expression of IL-23R as well as transcription factors RORγt and RORα, along with Th17 cells related genes Il17a, Il17f, and Il22, whereas the expression of IL-6R, IL-1R, and IL-21R was not altered. These results suggest that GHRH-R signaling is an upstream regulator of RORγt, RORα, and IL-23R. GHRH-R signaling regulated Th17-lineage cytokines through the RORγt-RORα-IL-23 pathway.
Although GHRH-R was expressed in activated T cells, our results indicated that GHRH-R deficiency was able to selectively inhibit the differentiation of Th17 cells without affecting Th1, Th2, and iTreg cells, probably due to the relatively lower expression of GHRH-R in Th1, Th2, and iTreg cells. In addition to the influence in Th17 cell differentiation under the non-pathogenic condition (IL-6 and TGF-β), GHRH-R deficiency reduced IL-17A production in Th17 cells under the pathogenic condition (IL-6, IL-1β, and IL-23). Furthermore, our data showed that even in the absence of exogenous GHRH-R ligands, GHRH-R expressing T cells stimulated with IL-6 and TGF-β still appeared to have higher IL-17A production than GHRH-R deficient T cells, while the expression of IL-6R, IL-1βR, and IL-21R were not affected, suggesting that GHRH was supplied by T cells in an autocrine/paracrine fashion. However, we could not detect the mRNA of GHRH in differentiated Th17 cells. Previous studies reported that GHRH, GH, and IGF-1 can be secreted by T cells in an autocrine/paracrine fashion to regulate the secretion of cytokines or T cell responses48,49,50. Recently, IGF-1 was found to act as an enhancer to skew the differentiation of Th17 over Treg in autoimmunity20. Based on this reported observation, we used the GHRH, GH, or IGF-1 antibodies to neutralize corresponding ligands in the cell culture medium and found that the IL-17A production by differentiated Th17 cells were reduced by the GHRH antibody, but not by the GH or IGF-1 antibodies, indicating that low level of GHRH in the medium had an impact in Th17 cell differentiation. The Th17 cell differentiation could be further enhanced by the GHRH agonist, while it was diminished by the GHRH antagonist or GHRH antibody in vitro. Our results established the impacts of GHRH-R signaling in promoting Th17 cell differentiation.
Given the importance of GHRH-R signaling in Th17 cell differentiation, we showed that the ocular inflammation in the EAU mice was mainly mediated by the GHRH-R signaling. We showed that the expression GHRH and GHRH-R were highly increased in the retina of EAU mouse as well as in eye-infiltrating CD4+ T cells, which were consistent with our in vitro results. Furthermore, our previous studies showed that the expression of GHRH and GHRH-R were elevated in the iris and ciliary body of rats challenged with LPS, suggesting GHRH and GHRH-R have an impact in ocular inflammation associated with both innate and adoptive immunity21,51,52. However, several questions remain. First, the source of retinal GHRH is not very clear. Although the hypothalamus is thought to be the primary source of GHRH, our results and those of other studies showed that GHRH is expressed in retinal ganglion cells and other retinal cells under physiological and pathological conditions53,54. Secondly, the impact of increased GHRH-R expression in the retina during EAU development is unknown. Although the GHRH-GH-IGF axis in the retina is critical for retinal physiology55,56, our adoptive transfer experiment indicated GHRH-R expression in the retina is not needed for EAU induction. Thirdly, the Ghrhrlit/lit mice used in this study are whole-body knockout mice instead of T cell-specific knockout mice, we cannot exclude other potential impacts of GHRH-R deficiency on other cell types, which may regulate inflammation in EAU and EAE models in vivo.
Importantly, the deficiency of GHRH-R or the application of the GHRH antagonist significantly alleviated, while GHRH agonist promoted, the clinical severity of EAU. First, the suppressed EAU caused by GHRH-R deficiency or by the GHRH antagonist was associated with a lower frequency of Th17 cells in the spleen, eye-draining lymph nodes, and eyes. In addition, within the eyes, reduced production of GM-CSF or IFN-γ in the CD4+IL-17+ T cells was in accordance with the inhibited GHRH signaling. In in vitro Th17 cell differentiation, unexpectedly, IFN-γ, GM-CSF, and IL-9 were not detectable in cells, which is different from results obtained from the EAU and EAE mouse models. These discrepancies could be due to multiple rounds of stimulation of Th17 cells to gain pathogenicity in animal models57. Alternatively, other potential cytokines produced by innate immune cells may be involved in the development of pathogenic Th17 cells, which cannot be mimicked in in vitro conditions. Furthermore, these declines were associated with downregulated expression of Il17f, Il22, and Csf2, which are the signatures of pathogenic Th17 cells, and were associated with upregulated expression of non-pathogenic Th17 cell-related gene Il10 in CD4+ T cells in the eyes of EAU mice. However, we could not rule out GHRH-R signaling is able to regulate the plasticity of the Th17 cells in EAU mice, although the frequency of IL-17A+IFN-γ+CD4+ T cells in eyes seemed to be regulated by GHRH-R signaling as well, which is different from our in vitro results that GHRH-R signaling did not alter the production of IFN-γ, the marker of Th1 cells, during differentiation. These differences highlighted the complexity of GHRH-R signaling in the differentiation and plasticity of Th17 cells in vivo.
In conclusion, our study demonstrated that GHRH-R signaling acts as an enhancer for Th17 cell differentiation and pathogenicity through the JAK-STAT3 pathway. We also highlighted the critical impacts of GHRH-R signaling in mediating pathogenic Th17 cells in autoimmune ocular and neural inflammation. Our findings shed light on a potential treatment targeting GHRH-R signaling by antagonist or antibodies for Th17 cell-associated autoimmune diseases.
Methods
Mice
Wild-type mice (C57BL/6J, Jax 000664) and Ghrhrlit/lit mice (C57BL/6J-Ghrhrlit/J, Jax 000533) were purchased from The Jackson Laboratories. Ghrhrlit/lit mice have a point mutation in both alleles of the Ghrhr gene32,33. Genotypes were confirmed by quantitative real-time PCR. In this study, both male and female mice, 6–10 weeks old, were used. All animals were kept in a specific pathogen-free facility at 22 °C and 40–50% humidity on a 12/12-h light/dark cycle and fed with standard laboratory chow ad libitum. All animal experiments were conducted in accordance with the guidelines of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. Ethics approval for this study was obtained from the Animal Experimentation Ethics Committee of the Chinese University of Hong Kong (approval numbers 20/014/GRF and 22/270/MIS).
Induction of EAU and disease assessment
Induction of EAU by active immunization was described previously in ref. 34. Briefly, EAU was induced by subcutaneously immunizing mice with 400 μg IRBP1-20 peptide emulsified in an equal volume of complete Freund’s adjuvant (CFA) containing 4.5 mg/ml heat-inactivated M.tuberculosis. Additionally, mice also received 300 ng Bordetella pertussis toxin intraperitoneally on the day of immunization. Mice were euthanized by cervical dislocation. For induction of EAU by adoptive transfer, spleen and lymph nodes cells were harvested from WT or Ghrhrlit/lit donor mice 10 days after immunization and dispersed into single-cell suspension, following enrichment of CD4+ T cells by the CD4+ T cell isolation kit (STEMCELL). Then these cells were cultured in vitro under Th17 polarizing conditions (50 ng/ml IL-6, 1 ng/ml TGF-β, 10 μg/ml of anti-IFN-γ, and 10 μg/ml of anti-IL4 Abs) and stimulated with 1 μg/ml of IRBP1-20 for 48 h. Then 10 ng/ml IL-23 was treated to cells for a further 24 h. Cells were then purified by centrifugation over Lympholyte-M cell separation media (Cedarlane), washed, and counted. About 5 × 106 cells were injected intraperitoneally into naïve recipient mice. 1 day later, the recipient mice received 200 ng of Bordetella pertussis toxin intraperitoneally. Clinical examinations by cSLO, OCT, and ERG were performed on anesthetized mice as previously described in ref. 58. Disease score of EAU was evaluated by fundus examination by the cSLO imaging system (Heidelberg Engineering GmbH) on a scale of 0–4, based on the number, type, and extent of lesions, as described previously in ref. 59. Retinal-choroidal thickness of EAU mice was measured and quantified by OCT imaging system at the same retinal location across various time points (Heidelberg Retina Angiograph 2; Heidelberg Engineering GmbH,) and vision was assessed by scotopic and photopic ERG with a Diagnosys Espion system and the ColorDome light emitting diode (LED) full-field stimulator (Diagnosys LLC)34.
Treatment protocols
MR-409 and MIA-602 were synthesized in the laboratory of A.V.S. For in vivo experiments, MR-409 and MIA-602 were dissolved in 100% DMSO for stock and diluted in PBS for injection. The concentration of DMSO was kept below 0.1%. Each mouse was subcutaneously injected with 20 μg MR-409 or MIA-602 dissolved in 100 μL PBS daily on days 10–21 post-immunization. Control mice were injected subcutaneously with 0.1 mL PBS containing 0.1% DMSO. For in vitro experiments, cells were cultured with 100 nM MR-409, hGHRH, or MIA-602 dissolved in 0.01% DMSO for 3 days unless otherwise specified. In some experiments, cells were cultured with ruxolitinib (1 μM) or Stattic (1 μM) for 3 days.
Induction of EAE and disease assessment
Age and gender-matched mice were immunized with 200 μg of MOG35-55 peptide emulsified in equal volumes of CFA containing 4.5 mg/ml M.tuberculosis. In addition, mice received two doses of 200 ng of Bordetella pertussis toxin intraperitoneally on the day of immunization and 2 days after immunization. Disease score of EAE were graded on a scale of 0-5 based on a standard scoring system60: 0=no disease, 1=limp tail, 2=hind limb weakness, 3=hind lib paralysis, 4=hind limb and fore limb paralysis, and 5=moribund or death.
Histology
For EAU mice, on day 21 after immunization, mice were anesthetized and perfused intracardially with PBS, followed by 4% paraformaldehyde (PFA). Eyeballs were immersed in 4% PFA for 24 h and embedded in paraffin. Tissues were sectioned in 5 μm thickness through the pupillary-optic nerve axis for hematoxylin and eosin (H&E) staining. For EAE mice, on day 21 after immunization, mice were anesthetized and perfused intracardially with PBS, followed by 4% PFA. Spinal cords were immersed in 4% PFA for 3–4 days. Tissues were embedded in paraffin and sectioned in 5 μm thickness for H&E or Luxol fast blue staining. All stained slides were captured by a light microscope (DMRB, Leica Microsystems) connected to a Spot digital camera (Diagnostic Instrument).
Tissue processing
Mice were sacrificed prior to isolation of the spleen, lymph nodes, eyes, or CNS tissues. Secondary lymphoid tissues were collected and grinded into suspension using a syringe and a 70-μm strainer. Red blood cells were lysed using RBC lysis buffer (BioLegend). The remaining cells were washed, filtered with a 40-μm strainer, and resuspended in complete RPMI (RPMI medium containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, nonessential amino acids, and 55 μM β-mercaptoethanol) for further experiments. For EAU experiments, eyes were collected from mice challenged with EAU 19–21 days after immunization. After the removal of extraocular tissues, the lens was enucleated from the eyes and the remaining tissue was minced into small pieces with scissors and incubated in a complete RPMI medium containing 1 mg/ml of collagenase D and 1 mg/ml of DNase (QIAGEN) for 45 min at 37 °C. Tissues were then dispersed vigorously by pipetting several times, filtered with a 70-μm strainer, and re-stimulated in the complete RPMI supplemented with 50 ng/ml phorbol myristate acetate (PMA, Sigma), 500 ng/ml ionomycin (Sigma), and 5 μg/ml brefeldin A (BioLegend) for 4 h prior to intracellular staining for flow cytometry. For EAE experiments, spinal cords and brains were collected from mice challenged with EAE 21 days after immunization. These tissues were minced into small pieces and incubated in the complete RPMI containing 1 mg/ml of collagenase D and 1 mg/ml of DNase for 45 min at 37 °C. Then the samples were disrupted by pipetting several times, strained over a 70 μm filter and purified by centrifugation with Percoll gradient at 13,000 × g at 4 °C for 10 min. After washed, cells were resuspended in complete RPMI containing 50 ng/ml PMA (Sigma), 500 ng/ml ionomycin (Sigma), and 5 μg/ml brefeldin A (BioLegend) for 4 h prior to intracellular staining for flow cytometry.
Flow cytometry
For cell surface staining, the isolated single-cell suspension was incubated in the cell staining buffer (BioLegend) containing anti-CD16/32 antibodies (1:100, BioLegend) for 15 min on ice to block Fc receptors and stained with conjugated fluorescent antibodies of cell surface markers as well as 7-AAD Viability Staining Solution (BioLegend) for 15 min on ice. For intracellular staining for cytokines, cell surface markers and LIVE/DEAD Fixable dye (Thermo Fisher) were stained prior to fixation with 4% PFA in staining buffer for 10 min at room temperature (RT). These cells were washed with intracellular staining permeabilization wash buffer (PB, BioLegend) three times and incubated in PB containing conjugated fluorescent antibodies of intracellular markers for 30 min at room temperature (RT). For intracellular staining of transcription factors, after cell surface marker staining, cells were fixed and permeabilized using True-Nuclear Transcription Factor Buffer Set (BioLegend) or FOXP3 Fix/Perm Buffer Set (BioLegend) for 1 h at RT. Then these cells were washed and stained with conjugated fluorescent antibodies of nuclear transcription factors in the perm buffer from the True-Nuclear Transcription Factor Buffer Set (BioLegend) for 45 min at RT. For intracellular phosphorylated signaling proteins, cell surface marker staining was done prior to fixation in 4% PFA in cell staining buffer for 10 min at RT. Then these cells were permeabilized in ice-cold 90% methanol for 30 min on ice, washed, and incubated with conjugated fluorescent antibodies in cell staining buffer supplemented with cOmplete protease inhibitor cocktail tablets (Roche) for 45 min at RT. All antibodies and buffer sets were listed in Supplementary Data 1. Flow cytometry data was acquired on Cytomics FC500 Flow Cytometry (Beckman), MoFlo Astrios (Beckman), or LSRII (BD Biosciences) and analyzed using Kaluza or FlowJo software.
In vitro T cell differentiation
Naïve CD4+ (CD62L+CD44−CD25−CD4+) T cells were isolated from spleens and lymph nodes of mice of designated genotypes by negative selection on LS Columns (Miltenyi Biotec) using naive CD4+ T cell isolation kits (Miltenyi Biotec/ STEMCELL) and identified by flow cytometry. Naïve CD4+ T cells (1 × 105 cells) were cultured in a 96-well plate pre-coated with 5 μg/ml anti-CD3 antibody (clone 145-2C11, BioLegend) in T cell medium (RPMI medium, 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, nonessential amino acids, and 55 μM β-mercaptoethanol) supplemented with 1 μg/ml anti-CD28 (clone 37.51, BioLegend). For Th0 culture, naïve CD4+ T cells were cultured in a T cell medium without any additional cytokines or antibodies. For Th1 cell differentiation, T cells were supplemented with 10 μg/ml of anti-IL-4 (clone 11B11, BioLegend) and 10 ng/ml of IL-12 (R&D). For Th2 cell differentiation, T cells were supplemented with 10 μg/ml of anti-IFN-γ (clone XMG1.2, BioLegend) and 10 ng/ml of IL-4 (R&D). For non-pathogenic Th17 cell differentiation, T cells were cultured with 10 μg/ml of anti-IL-4 (clone 11B11, BioLegend), 10 μg/ml of anti-IFN-γ (clone XMG1.2, BioLegend), 50 ng/ml of IL-6 (R&D), and 1 ng/ml of TGF-β (R&D). For pathogenic Th17 cell differentiation, T cells were supplemented with 10 μg/ml of anti-IL-4 (clone 11B11, BioLegend), 10 μg/ml of anti-IFN-γ (clone XMG1.2, BioLegend), 50 ng/ml of IL-6 (R&D), 1 ng/ml of TGF-β (R&D) and 10 ng/ml IL-23 (R&D) or combination of cytokines of 50 ng/ml of IL-6 (R&D), 10 ng of IL-1β (R&D) and 10 ng/ml of IL-23(R&D). For iTreg cell differentiation, T cells were supplemented with 10 μg/ml of anti-IL-4 (clone 11B11, BioLegend), 10 μg/ml of anti-IFN-γ (clone XMG1.2, BioLegend), 100 U/ml of IL-2 (Peprotech), and 5 ng/ml of TGF-β (R&D). For in vitro experiments, 100 nM MR-409, hGHRH, and MIA-602 dissolved in DMSO were used unless otherwise specified. T helper cell differentiation was performed under T cell-polarizing conditions for 3 days.
Cell proliferation assay
Naïve CD4+ T cells were labeled with 1 μM carboxyfluorescein succinimidyl ester (CFSE, BioLegend) following the manufacturer’s instruction. Cells were then cultured under Th0 or Th17 cell-polarizing conditions for 3 days before flow cytometry analysis.
Cell apoptosis assay
Naïve CD4+ T cells were cultured under Th17 cell differentiation condition for 3 or 5 days. Apoptosis was measured by staining cells with propidium iodide (PI, Invitrogen) or 7-AAD viability staining solution (BioLegend) and Annexin V (Invitrogen) following the manufacturer’s instructions.
Immunofluorescence
Naïve CD4+ T cells were isolated and cultured under Th17 differentiation condition for 3 days, washed, and fixed with 4% PFA at RT for 10 min. Cells were then permeabilized in PBS containing 0.2% Triton X-100 and 1% bovine serum albumin (BSA) for 10 min at RT, blocked by 5% BSA in PBS for 30 min and incubated with indicated primary antibodies overnight at 4 °C. After incubation with secondary antibodies and DAPI for 2 h at RT, cells were incubated on poly-l-lysine-coated slides and mounted using GB-Mount (GBI Labs) with coverslips. For retina immunofluorescence, paraffin sections of retina were dewaxed with xylene three times, hydrated, and heated in a pressure cooker for epitope retrieval. Tissues were then permeabilized, blocked, and incubated with primary and secondary antibodies. Subsequently, slides were mounted with coverslips using a DAPI-containing mounting medium. Anti-GHRH Ab (1:100, Abcam, ab187512), anti-GHRH-R Ab (1:100, Abcam, ab76263), FITC-conjugated anti-CD4 Ab (1:50, BioLegend, RM4-5), anti-rabbit secondary Ab (1:100, Alexa Fluor 488/594, Invitrogen), DAPI (1 µg/ml, Invitrogen). Images were captured with a Nikon A1MP confocal microscope using the NIS-Elements software (Nikon). The fluorescence intensity was quantified using ImageJ (National Institutes of Health).
Isolation of eye-infiltrating CD4+ T cells
EAU mice were sacrificed 19–21 days after immunization and eyes were collected. The lens was enucleated from the eyes and the remaining tissues were minced into small pieces for digestion in a complete RPMI medium containing 1 mg/ml of collagenase D and 1 mg/ml of DNase (QIAGEN) for 45 min at 37 °C. Tissues were then dispersed and filtered with a 70-μm strainer following the centrifugation through a Percoll gradient to acquire mononuclear cells. CD4+ T cells were isolated by negative selection using the Mouse CD4+ T Cell Isolation Kit (STEMCELL). The purity of CD4+ T cells was over 95% by flow cytometry. In this experiment, 5–6 eyes were pooled as one sample for RNA extraction.
RNA extraction and quantitative real-time PCR
For in vivo experiments, the retina was collected from the eyes of EAU mice 19–21 days after immunization and were homogenized for RNA extraction. For in vitro experiments, naïve CD4+ T cells were cultured under Th17 differentiation conditions for 3 days. Total RNA was extracted from these samples using RNeasy Mini Kit (QIAGEN) following the manufacturer’s instructions, quantified, and then converted to cDNA using SuperScript III Reverse Transcriptase (Roche). qRT-PCR was performed using LightCycler 480 Sybr Green I Master (Roche) using LightCycler 480 II real-time PCR (Roche Applied Science). Gene expression was normalized to that of the housekeeping gene Gapdh and fold change was calculated by using the 2−ΔΔCT threshold cycle method. Relative gene expression was normalized by comparing gene expression to the average of controls that was set to 1. A list of primers is presented in Supplementary Data 1.
siRNA treatment
GHRH-R expression was knocked down using Ghrhr siRNA (siRNA ID254217, Thermo Fisher) by nucleofection. The Silencer Negative Control No. 1 siRNA (AM4611, Thermo Fisher) was used in the control group. Naïve T cells (1 × 106 per well) isolated from the spleen and lymph nodes were mixed with 100 µL primary cell nucleofection solution (Lonza). For siRNA transfection, naïve T cells were incubated with 300 nM Ghrhr siRNA or Silencer Negative Control siRNA, transferred to Nucleofection cuvette strips (Lonza), and electroporated using a 4D Nucleofector (Lonza) with a DN-100 pulse. After transfection, cells were cultured in 96-well plates with pre-warmed 200 µl complete medium under the Th17 cell differentiation condition for 3 days.
Statistical analysis
The computer software Prism 8 (GraphPad) was used for statistical analysis and graph plotting. For two-group comparisons, if the data passes the normality test, we use the Student’s t-test; otherwise, we adopt the Mann–Whitney test for the comparison. When multiple hypotheses are tested, we use the Bonferroni correction to adjust for the multiple comparison and control the family-wise error rate at 0.05. As a result, when m hypotheses are tested simultaneously, the ones with the resulting p values smaller than 0.05/m are rejected. For comparisons between three or more groups, we first apply the one-way ANOVA, and we provide the corresponding F statistics and p values in the figure legends. When the null hypotheses are rejected, we further compare each pair of groups and show the Bonferroni-adjusted p values calculated by Prism 8 on the corresponding figures to account for multiple comparison. The pairwise comparisons with the Bonferroni-adjusted p values smaller than 0.05 are significant. To differentiate the unadjusted raw p values and the Bonferroni-adjusted p values, in the figures, we use “P” to denote the unadjusted raw p values and “\(\widetilde{{{{{{\rm{P}}}}}}}\)” to denote the Bonferroni-adjusted p values. All graphs show the mean ± standard error of mean (SEM) and represent three or more samples in at least two independent experiments unless described otherwise.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Data availability
All other data are provided in the article and its Supplementary files or from the corresponding author upon request. Source data are deposited in figshare https://doi.org/10.6084/m9.figshare.22739690. Source data are provided with this paper.
References
Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 (2005).
Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485–517 (2009).
Mangan, P. R. et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231–234 (2006).
Zhou, L. et al. IL-6 programs T(H)−17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).
Yang, X. O. et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358–9363 (2007).
Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480–483 (2007).
Yang, X. O. et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28, 29–39 (2008).
Ghoreschi, K. et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467, 967–971 (2010).
Lee, Y. et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991–999 (2012).
Caspi, R. R. A look at autoimmunity and inflammation in the eye. J. Clin. Invest 120, 3073–3083 (2010).
Hou, S. et al. Genetic variations of IL17F and IL23A show associations with Behcet’s disease and Vogt-Koyanagi-Harada syndrome. Ophthalmology 122, 518–523 (2015).
Geri, G. et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J. Allergy Clin. Immunol. 128, 655–664 (2011).
Caspi, R. R. et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140, 1490–1495 (1988).
Luger, D. et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799–810 (2008).
Horai, R. & Caspi, R. R. Cytokines in autoimmune uveitis. J. Interferon Cytokine Res. 31, 733–744 (2011).
Chong, W. P. et al. The cytokine IL-17A limits Th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24. Immunity 53, 384–397 e385 (2020).
Schally, A. V., Varga, J. L. & Engel, J. B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat. Clin. Pr. Endocrinol. Metab. 4, 33–43 (2008).
Bodart, G. et al. Somatotrope GHRH/GH/IGF-1 axis at the crossroads between immunosenescence and frailty. Ann. N. Y Acad. Sci. 1351, 61–67 (2015).
DiToro, D. et al. Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity. Immunity 52, 650–667 e610 (2020).
Liang, W. C. et al. Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. Proc. Natl Acad. Sci. USA 117, 6067–6074 (2020).
Weigent, D. A. Expression of lymphocyte-derived growth hormone (GH) and GH-releasing hormone receptors in aging rats. Cell Immunol. 282, 71–78 (2013).
Stepien, T., Lawnicka, H., Komorowski, J., Stepien, H. & Siejka, A. Growth hormone-releasing hormone stimulates the secretion of interleukin 17 from human peripheral blood mononuclear cells in vitro. Neuro Endocrinol. Lett. 31, 852–856 (2010).
Ikushima, H., Kanaoka, M. & Kojima, S. Cutting edge: requirement for growth hormone-releasing hormone in the development of experimental autoimmune encephalomyelitis. J. Immunol. 171, 2769–2772 (2003).
Shohreh, R., Pardo, C. A., Guaraldi, F., Schally, A. V. & Salvatori, R. GH, but not GHRH, plays a role in the development of experimental autoimmune encephalomyelitis. Endocrinology 152, 3803–3810 (2011).
Bodart, G. et al. The severe deficiency of the somatotrope GH-releasing hormone/growth hormone/insulin-like growth factor 1 axis of Ghrh(-/-) mice is associated with an important splenic atrophy and relative B lymphopenia. Front. Endocrinol. 9, 296 (2018).
Brown, P. A., Davis, W. C. & Draghia-Akli, R. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. Mol. Ther. 10, 644–651 (2004).
Khorram, O., Yeung, M., Vu, L. & Yen, S. S. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J. Clin. Endocrinol. Metab. 82, 3590–3596 (1997).
Zhang, C. et al. Activity of the growth hormone-releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosis-like granuloma. Clin. Transl. Immunol. 10, e1310 (2021).
McElvaine, A. T. & Mayo, K. E. A dominant-negative human growth hormone-releasing hormone (GHRH) receptor splice variant inhibits GHRH binding. Endocrinology 147, 1884–1894 (2006).
Xiong, X. et al. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proc. Natl Acad. Sci. USA 117, 6726–6732 (2020).
Lin, S. C. et al. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 364, 208–213 (1993).
Godfrey, P. et al. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat. Genet. 4, 227–232 (1993).
Li, J. et al. Quantitative characterization of autoimmune uveoretinitis in an experimental mouse model. Invest Ophthalmol. Vis. Sci. 58, 4193–4200 (2017).
Mattapallil, M. J. et al. Characterization of a new epitope of IRBP that induces moderate to severe uveoretinitis in mice with H-2b haplotype. Invest Ophthalmol. Vis. Sci. 56, 5439–5449 (2015).
Weigent, D. A. & Blalock, J. E. Expression of growth hormone by lymphocytes. Int. Rev. Immunol. 4, 193–211 (1989).
Taub, D. D., Murphy, W. J. & Longo, D. L. Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Curr. Opin. Pharm. 10, 408–424 (2010).
Hirota, K. et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 204, 2803–2812 (2007).
Morishima, N., Mizoguchi, I., Takeda, K., Mizuguchi, J. & Yoshimoto, T. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem. Biophys. Res. Commun. 386, 105–110 (2009).
Barabutis, N. & Schally, A. V. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 9, 4110–4116 (2010).
Welniak, L. A., Sun, R. & Murphy, W. J. The role of growth hormone in T-cell development and reconstitution. J. Leukoc. Biol. 71, 381–387 (2002).
Zarandi, M. et al. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides 89, 60–70 (2017).
Cai, R. et al. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides 52, 104–112 (2014).
Elyaman, W. et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl Acad. Sci. USA 106, 12885–12890 (2009).
Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900–911 (2003).
Constantinescu, C. S., Farooqi, N., O’Brien, K. & Gran, B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharm. 164, 1079–1106 (2011).
Blalock, J. E. The immune system as the sixth sense. J. Intern Med. 257, 126–138 (2005).
Weigent, D. A. Lymphocyte GH-axis hormones in immunity. Cell Immunol. 285, 118–132 (2013).
Granata, R. Peripheral activities of growth hormone-releasing hormone. J. Endocrinol. Invest. 39, 721–727 (2016).
Taub, D. D. Neuroendocrine interactions in the immune system. Cell Immunol. 252, 1–6 (2008).
Ren, J. L. et al. Growth hormone-releasing hormone receptor mediates cytokine production in ciliary and iris epithelial cells during LPS-induced ocular inflammation. Exp. Eye Res. 181, 277–284 (2019).
Qin, Y. J. et al. Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proc. Natl Acad. Sci. USA 111, 18303–18308 (2014).
Thounaojam, M. C. et al. Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy. Proc. Natl Acad. Sci. USA 114, 13248–13253 (2017).
Cen, L. P. et al. Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1920834118 (2021).
Hellstrom, A. et al. IGF-I is critical for normal vascularization of the human retina. J. Clin. Endocrinol. Metab. 87, 3413–3416 (2002).
Harvey, S. & Martinez-Moreno, C. G. Growth hormone and ocular dysfunction: endocrine, paracrine or autocrine etiologies? Growth Horm. IGF Res. 29, 28–32 (2016).
Hirota, K. et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12, 255–263 (2011).
Du, L. et al. Ruxolitinib alleviates uveitis caused by Salmonella typhimurium endotoxin. Microorganisms https://doi.org/10.3390/microorganisms9071481 (2021).
Agarwal, R. K., Silver, P. B. & Caspi, R. R. Rodent models of experimental autoimmune uveitis. Methods Mol. Biol. 900, 443–469 (2012).
Stromnes, I. M. & Goverman, J. M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1, 1810–1819 (2006).
Acknowledgements
We thank members of the Chu laboratory for helpful discussions. We thank Professor Kam Tong Leung and Ms Siu Ping Fok for their technical support on the siRNA transfection experiment. We also express our gratitude to Dr Yuzhou Zhang from the Chinese University of Hong Kong, Professor Fengping Shan, and Professor Xun Sun from the China Medical University for their critical comments on this study. This work was supported by the General Research Fund, Research Grants Council, Hong Kong (14104621 and 14102522 to W.K.C., and 14305319 to Y.W.), The Chinese University of Hong Kong Direct Grant (2020.067 and 2021.046 to W.K.C.), National Natural Science Foundation of China (82201198 to J.L.) and Zhejiang Provincial Natural Science Foundation of China (LTGY23H120004 to J.L.). The work of A.V.S. was supported by the Medical Research Service of the US Department of Veterans Affairs.
Author information
Authors and Affiliations
Contributions
Conceptualization, L.D., J.L., and W.K.C. Investigation, L.D., B.M.H., L.Z., Y.W.Y.Y., and J.N.H. Formal analysis, L.D., Y.W., C.C.T., S.O.C., A.V.S., C.P.P., J.L., and W.K.C. Resources, A.V.S. Writing—original draft preparation, L.D., S.O.C., C.P.P., J.L., and W.K.C. Supervision, S.O.C., C.P.P., J.L., and W.K.C. Funding acquisition, Y.W., J.L. and W.K.C. Materials and correspondence requests should be addressed to W.K.C.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Du, L., Ho, B.M., Zhou, L. et al. Growth hormone releasing hormone signaling promotes Th17 cell differentiation and autoimmune inflammation. Nat Commun 14, 3298 (2023). https://doi.org/10.1038/s41467-023-39023-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-023-39023-1
This article is cited by
-
The implications of FASN in immune cell biology and related diseases
Cell Death & Disease (2024)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.